ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos60.47 M71.25 M71.23 M73.66 M74.36 M290.51 MInvestigación y desarrollo11.68 M12.92 M13.96 M14.18 M13.12 M54.18 MBeneficio operativo-36.5 M6.58 M13.9 M16.82 M17.87 M55.17 MTotal de ingresos no operativos-2.11 M1.36 M4.32 M287 K1.25 M7.22 MGastos por intereses, netos de intereses capitalizados5.46 M5.25 M5.35 M5.41 M5.5 M21.51 MIngresos no operativos, una vez deducidos los gastos por intereses-3.04 M-3.6 M-4.54 M-4.32 M-4.65 M-17.11 MIngresos/gastos extraordinarios-4.53 M-286 K3.5 M-804 K403 K2.81 MBeneficio antes de impuestos-38.61 M7.94 M18.21 M17.11 M19.11 M62.38 MParticipación en los beneficios——————Impuestos-4.74 M2.11 M3.35 M2.2 M5.83 M13.49 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos337 K-1.03 M681 K-2.18 M902 K-1.63 MBeneficio neto antes de actividades interrumpidas-33.87 M5.83 M14.87 M14.91 M13.29 M48.89 MOperaciones suspendidas——————Beneficio neto-33.87 M5.83 M14.87 M14.91 M13.29 M48.89 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-33.87 M5.83 M14.87 M14.91 M13.29 M48.89 MBeneficio básico por acción-0.610.10.260.270.240.87Beneficio por acción diluido-0.610.10.260.260.240.86Número medio de acciones ordinarias55.94 K56.12 K56.23 K56.27 K56.23 K224.86 KAcciones diluidas55.94 K56.56 K56.51 K56.53 K56.56 K226.16 KEBITDA2.57 M19.72 M28.32 M27.14 M57.38 M132.56 MEBIT-36.5 M6.58 M13.9 M16.82 M17.87 M55.17 MCosto de los ingresos128.71 M78.42 M91.22 M88.29 M94.08 M352.01 MOtros costes de producción——————Amortización y depreciación (flujo de caja)39.07 M13.14 M14.42 M10.32 M39.52 M77.39 M
Repligen Corporation
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.